China’s SFDA Denies Illegal Exports Of Performance-Enhancing Drugs
This article was originally published in PharmAsia News
Chinese regulators deny U.S. reports that China's bulk-drugs suppliers were illegally exporting performance-enhancing drugs to the United States. Wu Zhen, deputy head of the State FDA, said most of such shipments were clearly labeled and had company contracts, export licenses and "warrants from the importing countries." Wu said it was the responsibility of importing countries to police the illegal use of any legally imported drugs. China is emphasizing its own crackdown on use of steroids and other performance-enhancing drugs in advance of the summer Olympics. (Click here for more
You may also be interested in...
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.
Sun Pharma and its US Taro subsidiary have further criticized a recent CMS policy proposal that would see Medicare Part B drugs approved under the US hybrid 505(b)(2) pathway reimbursed at a lower rate applicable to multiple source products.
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.